VIR · Vir Biotechnology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ($29.0K) | - | $2.38M | $3.08M | $56.38M | - | $2.38M | $3.08M | $56.38M | - |
| Cost of Revenue | - | - | - | $11.0K | $0 | - | $50.0K | $52.0K | $59.0K | - |
| Gross Profit | - | - | - | $3.06M | $56.38M | - | $2.33M | $3.02M | $56.32M | - |
| R&D | $108.92M | - | $151.46M | $97.51M | $118.64M | - | $195.18M | $105.11M | $100.13M | - |
| SG&A | $23.34M | - | $22.23M | $22.28M | $23.94M | - | $25.74M | $30.27M | $36.27M | - |
| Total Operating Expenses | $132.26M | - | $173.68M | $119.63M | $142.58M | - | $233.68M | $161.71M | $136.46M | - |
| D&A | $2.81M | - | $2.90M | $2.90M | $2.87M | - | $2.90M | $4.20M | $4.52M | - |
| Operating Income | ($132.29M) | - | ($173.44M) | ($118.42M) | ($139.55M) | - | ($231.30M) | ($158.63M) | ($80.08M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $170.0K | - | $168.0K | $170.0K | $16.0K | - | $177.0K | ($1.51M) | $276.0K | - |
| Net Income | ($125.69M) | - | ($163.14M) | ($110.96M) | ($120.97M) | - | ($213.72M) | ($138.38M) | ($65.28M) | - |
| EPS - Basic | ($0.85) | - | ($1.17) | ($0.80) | ($0.88) | - | ($1.56) | ($1.02) | ($0.48) | - |
| EPS - Diluted | ($0.85) | - | ($1.17) | ($0.80) | ($0.88) | - | ($1.56) | ($1.02) | ($0.48) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $274.16M | $232.19M | $170.08M | $211.10M | $273.57M | $222.95M | $168.35M | $296.86M | $160.71M | $241.58M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.45M | $9.80M | $6.85M | $12.23M | $3.73M | $5.08M | $7.30M | $4.39M | $7.11M | $6.33M |
| Current Assets | $522.99M | $514.08M | $545.68M | $735.71M | $932.21M | $1.04B | $1.05B | $1.21B | $1.21B | $1.59B |
| Total Assets | $1.03B | $1.00B | $1.02B | $1.19B | $1.31B | $1.40B | $1.50B | $1.67B | $1.79B | $1.92B |
| Current Liabilities | $73.56M | $92.81M | $75.22M | $105.00M | $137.29M | $119.66M | $117.16M | $96.41M | $94.07M | $175.41M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $212.82M | $237.55M | $223.35M | $245.06M | $263.91M | $248.43M | $257.63M | $235.88M | $246.61M | $328.82M |
| Stockholders' Equity | $812.76M | $765.28M | $796.10M | $947.47M | $1.55B | $1.15B | $1.24B | $1.43B | $1.55B | $1.59B |
| Retained Earnings | ($1.32B) | ($1.20B) | ($1.15B) | ($991.71M) | ($880.75M) | ($759.78M) | ($655.20M) | ($441.48M) | ($303.10M) | ($237.82M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($132.39M) | - | - | - | ($78.12M) | - | - | - | ($109.39M) | - |
| Investing Cash Flow | $11.84M | - | - | - | $126.82M | - | - | - | $28.42M | - |
| Financing Cash Flow | $162.52M | - | - | - | $598.0K | - | - | - | $152.0K | - |
| CapEx | $390.0K | - | - | - | $1.63M | - | - | - | $1.87M | - |
| Free Cash Flow | ($132.78M) | - | - | - | ($79.75M) | - | - | - | ($111.26M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | 99.6% | 100.0% | - | 97.9% | 98.3% | 99.9% | - |
| Operating margin | 456172.4% | - | -7287.5% | -3851.0% | -247.5% | - | -9718.7% | -5158.7% | -142.0% | - |
| EBITDA margin | 446479.3% | - | -7165.7% | -3756.7% | -242.4% | - | -9596.8% | -5022.1% | -134.0% | - |
| Net margin | 433431.0% | - | -6854.7% | -3608.4% | -214.6% | - | -8979.7% | -4500.1% | -115.8% | - |
| Free cash flow margin | 457848.3% | - | - | - | -141.5% | - | - | - | -197.4% | - |
| FCF / Net income | 1.06 | - | - | - | 0.66 | - | - | - | 1.70 | - |
| R&D / Revenue | -375593.1% | - | 6364.0% | 3171.0% | 210.5% | - | 8200.8% | 3418.3% | 177.6% | - |
| SG&A / Revenue | -80479.3% | - | 934.1% | 724.7% | 42.5% | - | 1081.7% | 984.2% | 64.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.3% | - | -16.0% | -9.3% | -9.3% | - | -14.3% | -8.3% | -3.6% | - |
| Return on equity | -15.5% | - | -20.5% | -11.7% | -7.8% | - | -17.2% | -9.7% | -4.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.11 | 5.54 | 7.25 | 7.01 | 6.79 | 8.71 | 8.94 | 12.51 | 12.90 | 9.05 |
| Quick ratio | 7.11 | 5.54 | 7.25 | 7.01 | 6.79 | 8.71 | 8.94 | 12.51 | 12.90 | 9.05 |
| Cash ratio | 3.73 | 2.50 | 2.26 | 2.01 | 1.99 | 1.86 | 1.44 | 3.08 | 1.71 | 1.38 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.26 | 1.31 | 1.28 | 1.26 | 0.85 | 1.22 | 1.21 | 1.16 | 1.16 | 1.21 |
| Liabilities / Assets | 0.21 | 0.24 | 0.22 | 0.21 | 0.20 | 0.18 | 0.17 | 0.14 | 0.14 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | -0.00 | - | 0.00 | 0.00 | 0.04 | - | 0.00 | 0.00 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | 405946d | - | - | 53327d | 30807d | 44010d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.6x | - | 1.0x | 0.7x | 0.6x | - | 0.8x | 0.8x | 0.9x | - |
| P / S | - | - | 333.3x | 226.9x | 15.8x | - | 430.1x | 394.3x | 24.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.1% | - | 0.0% | 0.0% | 0.0% | - | -9.8% | -19.0% | -10.5% | - |
| Revenue CAGR (3y) | - | - | -81.5% | - | -64.2% | - | -71.6% | -74.1% | 205.6% | - |
| Revenue CAGR (5y) | - | - | 4.3% | -46.0% | 58.0% | - | -3.8% | - | - | - |
| Gross profit growth (YoY) | - | - | - | 1.4% | 0.1% | - | -10.4% | -19.9% | -7.8% | - |
| Operating income growth (YoY) | 5.2% | - | 25.0% | 25.4% | -74.3% | - | -23.9% | 26.3% | 44.1% | - |
| Net income growth (YoY) | -3.9% | - | 23.7% | 19.8% | -85.3% | - | -30.8% | 29.0% | 53.7% | - |
| EPS growth (YoY) | 3.4% | - | 25.0% | 21.6% | -83.3% | - | -27.9% | 29.7% | 54.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -66.5% | - | - | - | 28.3% | - | - | - | 16.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -47.5% | -33.5% | -35.8% | -33.9% | 0.0% | -27.7% | -42.3% | -20.8% | -21.5% | -23.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$68.56M totalReportable Segment$68.56M · 100.0%
Product / service
$67.42M totalLicense And Collaboration Revenue$63.13M · 93.6%
Other Revenue$3.39M · 5.0%
Grant$2.04M · 3.0%
Profit Sharing Amount($1.14M) · -1.7%
Geographic
$66.30M totalNon Us$64.27M · 96.9%
US$2.04M · 3.1%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Vir Biotechnology against the 5 most active filers in the same SIC group.